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Introduction
Cardiovascular diseases are among the most frequent causes of hospitalization and death. Scientific knowledge underlying coronary atherosclerotic complications, notably acute cardiac syndrome, has improved a great deal in recent years. The causes are believed to include endothelial dysfunction, inflammation and increased permeability of vessel wall and neurohormonally mediated endothelial reactions. Such pro cesses favour interactions of blood-borne elements with the vessel wall, especially molecules that parti ci pate in adhesion, aggregation and the blood clotting cascade. Aggravated ischaemic heart disease and myocardial infarction can be caused by several factors [1] .
In the majority of cases the infarction is caused by destabilized blood vessel plaque and formation of a clot which totally or partially occludes the blood vessel lumen [2] .
Many studies have demonstrated the link between cardiovascular risk and level of fibrinogen. It is believed that this protein (a thrombin substrate) is involved in the final stages of the clotting process. Fibrinogen binds platelets causing their aggregation, modulates endothelial functioning and affects plasminogen binding. In addition, fibrinogen is believed to be an acute phase protein [3] .
Endothelial dysfunction and its impaired anticoagulant function also lead to elevated expression of various cell adhesion molecules (intercellular adhesion molecules [ICAM] , vascular cell adhesion molecule [VCAM-1], selectins and integrins) on the surface of the initial atherosclerotic lesion [4] .
Leukocytes and cells originating from the blood vessel wall secrete proinflammatory cytokines and growth factors which further increase leukocyte recruitment as well as causing migration and prolife ration of smooth muscle cells. During plaque progression, the inflammatory mediators trigger expression of tissue factor, a protein with potential procoagulant action, as well as expression of proteinases re sponsible for matrix breakdown, thereby favouring tran sition from a stable to an unstable plaque. Plaque rupture at the site of its cover allows circulating clotting factors easy access to the thrombogenic lipid core containing the tissue factor. Thrombus formation at the site of plaque rupture is dependent on the local equilibrium between proclotting/fibrinolytic factors and may lead to cardiac infarction [5] .
Expression of intercellular adhesion molecule-2 (ICAM-2) was examined in mononuclear peripheral blood cells from ACS patients. The obtained data were analysed in the context of the occurrence of classical cardiovascular risk factors.
Material and methods
The research project was designed according to Declaration of Helsinki-based GCP guidelines and was positively endorsed by the Bioethics Commission of the Medical University of Silesia in Katowice on 21 December 2004 (resolution NN-6501-223/I/04).
Prospective study subjects were included in the investigation when voluntary written consent to participate had been obtained.
The experimental group was set up based on specific inclusion and exclusion criteria. The following study inclusion criteria were established: a) age above 18 years, b) conscious consent, c) firsttime cardiac incident, i.e. lack of previous treatment for coronary disease), d) typical coronary chest pain lasting less than 12 h, e) ECG changes in ST-T segment and T wave, or block of left atrioventricular bundle branch.
The exclusion criteria included: a) no consent to participate, b) acute or chronic inflammatory disease, or autoimmune disease, c) renal insufficiency, d) se vere hypertension, e) advanced circulatory failure, f) chest pain of non-cardiac origin.
ECG and cardiac Echo were performed upon clinic admittance of all subjects participating in the study, besides urgent coronarography and basic laboratory tests. Concentration of cardiac necrosis markers was also determined in the subjects.
The control group included healthy individuals (none of them was ever treated before for cardiology-related problems), who reported to the emergency department with chest pain such as neurosis or indigestion. They were included in the control group based on interview, physical examination and results of laboratory tests (blood morphology/blood smear, erythrocyte sedimentation rate [ESR], lipid profile, serum glucose concentration, creatinine, electrolytes) and no changes in coronary vessel angio graphy or 64-row multidetector computed tomo graphy picture, the latter assessing coronary artery calcification (calcium score). All study participants were domiciled in the Upper Silesia region.
As material for study, RNA isolated from peripheral blood mononuclear cells was used. Transcriptional activity of the examined gene was assessed using a commercially available kit (TaqMan Gene Expression Assays, Applied Biosystems, Foster City, CA, USA). The number of ICAM-2 mRNA molecules was determined based on QRT-PCR reaction kinetics using the ABI PRISM™ 7000 sequence detection system (Applied Biosystems) and a kit containing fluorescent dye (ROX QuantiTect Probe RT-PCR, Quiagen, Germany). QRT-PCR was performed in one step using a reaction mix containing 25 µl 2× S St ta at ti is st ti ic ca al l a an na al ly ys si is s
The
Results
Subjects eligible for study participation were patients (n = 60) with acute cardiac syndrome who were admitted to the clinic. Twenty healthy volunteers served as the control group.
The mean age was 53 years (38-69 years) in the ACS patient group and 49 years (40-65 years) in the control group. Subjects who participated in the study included 15 females and 45 males with ACS and 10 fe males and 10 males in the control group.
Analysis of the results demonstrated a significantly higher number of ICAM-2 gene copies in samples from ACS patients, as compared to samples from the control group. The numbers were 140920 ±105207 and 15023 ±14325, respectively (Table I) .
The results obtained were confirmed by electrophoretically separating the amplification products using a polyacrylamide gel (Figure 1 ).
Based on QRT-PCR reaction kinetics a correlation graph was generated for ICAM-2 and β-actin values in the two studied groups. For better visualization the values were lined up in ascending order (Figure 2) .
Analysis of the investigated transcriptional activity of ICAM-2 adhesion molecule and the occurrence of classic risk factors in cardiovascular diseases revea led a statistically significant difference for obese subjects with burdening family history (Table II) .
Discussion
Atherosclerosis is a multifocal chronic inflammatory process affecting mainly large and medium arteries. It begins to develop in early stages of life and progresses with age. Initiation of plaque formation starts with endothelial dysfunction when molecules promoting migration and adhesion of proinflammatory cells appear. At these early stages of plaque development, T lymphocytes and macro pha - ges infiltrate the subendothelial layer, and this testifies to the activation of the immune system. Our study has demonstrated elevated expression of adhesion molecule ICAM-2 in ACS patients, as compared to controls. These results corroborate our earlier findings obtained using oligonucleotide microarrays and stress the role of ICAM-2 in cardiovascular diseases [6] . There are few published data concerning involvement of ICAM-2 in coronary disease. It is known, though, that this molecule, together with ICAM-1, takes part in lymphocyte recirculation, immune response, NK-cell mediated clearance and surveillance processes. Most likely, increased expression of the ICAM-2 gene is linked to elevated secretion of chemokines, leukocyte adhesion, increased permeability of the cell layer, elevated cytokine synthesis as well as proliferation and migration of smooth muscle cells. The ICAM-1 and ICAM-2 molecules are expressed on the endothelial cell surface only in small amounts and their expression is stimu lated by interferon-γ, interleukin-1 (IL-1), tumour necrosis factor α (TNF-α) and oxidized cholesterol (ox-LDL). The ICAM-1 and ICAM-2 ligands include glycoprotein from the β 2 -integrin family, lymphocyte function antigen-1 (LFA-1) and leukocyte α M β 2 integrin (Mac-1) present on the surface of neutrophils and monocytes [7] . Circadian variability of serum concentration of adhesion molecules was found; Pselectin was elevated during evening hours, which is explained by its decreased binding to cell mem brane [8] , whereas no such circadian fluctuation was observed in the case of E-selectin and ICAM-1 con centration. Currently, studies are underway aimed at elucidating the mechanism of adhesion molecules' expression regulation. It has been shown, for example, that actin cytoskeleton is involved in modulating ICAM-1 expression in endothelial cells through its destabilization and prevention of asymmetric dimethylarginine (ADMA)-in duced NF-κB activation. This hypo thesis has been confirmed in studies involving ADMA-treated human umbilical vein endothelial cell (HUVEC) cultures [9] . Inhibited expression of ICAM-1 can also result from treating cells with ganciclovir.
It cannot be excluded, though, that the antiprolifera tive effect can result from drug cytotoxicity [10] .
There have been several reports in the literature exploring the relationship between transcriptional activity of genes responsible for expression of adhesion molecules and classical risk factors in cardiovascular diseases. The most frequently investigated factors have been aortal hypertension, tobacco smoking, diabetes and obesity [11] [12] [13] . The study of Jin et al. [14] suggested elevated expression of ICAM-1 molecules in patients suffering from type-2 diabetes. In our analysis, no statistically significant difference was noted between the level of ICAM-2 molecule expression and diabetes occurrence. No correlation could be found between the expression of ICAM-2 and the smoker/non-smoker status of subjects from the studied group of patients with ACS, although the effect of this factor on the expression of various genes has long been recognized [15, 16] . Similarly, no differences were observed concerning expression of the investigated gene in dependence of the so-called non-modifiable risk factors (such as age and sex). It is worth stressing that a statistically significant difference in expression of the ICAM-2 gene was observed in obese patients with ACS. Similar results concerning expression of adhesion molecules and pro-inflammatory genes in atherosclerotic patients were obtained by Orea Soler et al. [17] . These resear chers noticed the effect of body mass loss on the changes in expression of these genes. The next statistically significant difference stressing the role played by adhesion molecules in atherosclerotic processes was observed in persons with burdening family history [11] . The ICAM-2 molecule expression investigated by us also revealed statistically significant diffe rences depending on burdening family history.
Increased ICAM-2 gene expression seen in patients with myocardial infarction may be responsible for processes leading to occlusion of coronary vessels and to thrombosis. Further studies on the role of ICAM-2 thus seem warranted.
In conclusion, increased ICAM-2 gene expression in ACS patients is probably symptomatic of endothelium dysfunction and may be responsible for intensified adhesion and aggregation processes as well as for appearance of acute coronary syndrome. These results indicate a correlation between obesity and burdening family history on the one hand, and increa sed ICAM-2 levels in patients with ACS, on the other.
